A Study to Assess DV-601 in Subjects With Chronic Hepatitis B

Exclusion Criteria

• •Liver disease other than CHB
• •Documented co-infection with hepatitis A virus (HAV), hepatitis C virus (HCV), or HIV
• •Previous therapy with interferon alpha.
• •Any other antiviral therapy for chronic hepatitis B within the previous 3 months prior to Screening Visit.
• •Immunosuppressive treatment (e.g. chemotherapy, high-dose of steroids) within 6 months of Screening Visit.
• •Evidence of cirrhosis
• •Child-Turcotte-Pugh (CTP) score ≥ 7, either currently or at any occasion in the past
• •Clinically significant acute or chronic illnesses, such as autoimmune diseases, collagen vascular disease, immune deficiencies, active or uncontrolled infections, etc. as determined by the investigator and documented in medical history.
• •Malignancy other than curatively treated, superficial skin cancer or carcinoma in situ of the cervix.
• •Participation in any experimental protocol or therapy within 28 days prior to the Screening Visit.
• •Current substance or alcohol abuse that in the opinion of the investigator would interfere with compliance or with interpretation of study results.